BioXcel Therapeutics, Inc. (BTAI) Earnings History
Annual and quarterly earnings data from 2016 to 2024
Loading earnings history...
BTAI EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
BTAI Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2024 | 5.4% | -2967.6% | -2630.1% |
| 2023 | 8.7% | -12448.0% | -12974.9% |
| 2022 | 94.7% | -42572.0% | -44201.9% |
| 2021 | - | - | - |
| 2020 | - | - | - |
Download Data
Export BTAI earnings history in CSV or JSON format
Free sign-in required to download data
BioXcel Therapeutics, Inc. (BTAI) Earnings Overview
As of May 8, 2026, BioXcel Therapeutics, Inc. (BTAI) reported trailing twelve-month net income of -$68M, reflecting +76.1% year-over-year growth. The company earned $-4.80 per diluted share over the past four quarters, with a net profit margin of -2630.1%.
Looking at the long-term picture, BTAI's historical earnings data spans multiple years. The company achieved its highest annual net income of -$2M in fiscal 2016.
BioXcel Therapeutics, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including ACAD ($376M net income, 36.5% margin), INVA ($504M net income, 63.8% margin), AXSM (-$188M net income, -28.7% margin), BTAI has room to improve margins relative to the peer group. Compare BTAI vs ACAD →
BTAI Earnings vs Peers
Earnings metrics vs comparable public companies
BTAI Historical Earnings Data (2016–2024)
9 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | -$60M | +66.7% | -$67M | $-23.51 | -2630.1% | -2967.6% |
| 2023 | -$179M | -8.0% | -$172M | $-98.35 | -12974.9% | -12448.0% |
| 2022 | -$166M | -55.0% | -$160M | $-94.67 | -44201.9% | -42572.0% |
| 2021 | -$107M | -30.1% | -$106M | $-64.87 | - | - |
| 2020 | -$82M | -154.1% | -$82M | $-60.63 | - | - |
| 2019 | -$32M | -67.8% | -$34M | $-32.38 | - | - |
| 2018 | -$19M | -324.5% | -$20M | $-21.16 | - | - |
| 2017 | -$5M | -114.1% | -$5M | $-4.41 | - | - |
| 2016 | -$2M | - | -$2M | $-2.06 | - | - |
See BTAI's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs BTAI Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare BTAI vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonBTAI — Frequently Asked Questions
Quick answers to the most common questions about buying BTAI stock.
Is BTAI growing earnings?
BTAI EPS is $-4.80, with earnings growth accelerating to +76.1%. This exceeds the 5-year CAGR of N/A. TTM net income reached $-68M.
What are BTAI's profit margins?
BioXcel Therapeutics, Inc. net margin is -2630.1%, with operating margin at -2967.6%. Below-average margins reflect competitive or cost pressures.
How consistent are BTAI's earnings?
BTAI earnings data spans 2016-2024. The accelerating earnings trend is +76.1% YoY. Historical data enables comparison across business cycles.